Evidence map›Paper›PMID 23050230›Full record

ArticleG3 (Bethesda, Md.)2012

PUF-8, a Pumilio homolog, inhibits the proliferative fate in the Caenorhabditis elegans germline.

Hilary Racher, Dave Hansen

Abstract read
In one paragraph

Article in G3 (Bethesda, Md.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Programmed DNA elimination was present in the last common ancestor ofbioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Biology · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Functional significance of PUF partnerships inbioRxiv : the preprint server for biology · 2023
    Article
  8. Article
  9. Review
  10. Review
  11. Molding immortality from a plastic germline.Current opinion in cell biology · 2021
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Biology of theGenetics · 2019
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hilary RacherDepartment of Biological Sciences, University of Calgary, Calgary, Alberta, Canada, T2N 1N4.
Dave Hansen

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

Stem cell populations are maintained by keeping a balance between self-renewal (proliferation) and differentiation of dividing stem cells. Within the Caenorhabditis elegans germline, the key regulator maintaining this balance is the canonical Notch signaling pathway, with GLP-1/Notch activity promoting the proliferative fate. We identified the Pumilio homolog, PUF-8, as an inhibitor of the proliferative fate of stem cells in the C. elegans germline. puf-8(0) strongly enhances overproliferation of glp-1(gf) mutants and partially suppresses underproliferation of a weak glp-1(lf) mutant. The germline tumor that is formed in a puf-8(0); glp-1(gf) double mutant is due to a failure of germ cells to enter meiotic prophase. puf-8 likely inhibits the proliferative fate through negatively regulating GLP-1/Notch signaling or by functioning parallel to it.

Indexed as

AllelesAnimalsCaenorhabditis elegansCaenorhabditis elegans ProteinsCell ProliferationChromosome MappingGene Expression RegulationGerm CellsMembrane GlycoproteinsMitosisModels, BiologicalPhenotypePolymorphism, Single NucleotideReceptors, NotchRNA-Binding ProteinsSignal TransductionCaenorhabditis elegans ProteinsGlp-1 protein, C elegansMembrane GlycoproteinsPUF-8 protein, C elegansReceptors, NotchRNA-Binding Proteinsgermline stem cellsNotch signalingproliferative fatePUFpuf-8Pumilio

Identifiers

PMID23050230
PMCPMC3464112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.